ArticlePloS one2026
Effects of taurine supplementation on metabolic health and biological aging in healthcare workers: A protocol for a triple-blinded, Bayesian-optimized phase II randomized controlled trial.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic-related diseases become increasingly prevalent with age. Recent experimental evidence suggests that taurine (2-aminoethanesulfonic acid) deficiency contributes to these conditions, despite taurine being classified as a conditionally essential amino acid. PURPOSE: This study aims to assess whether a 6-month oral taurine supplementation program improves blood glucose control and other health parameters among healthcare workers.
methodsThis study is a Bayesian-optimized phase II 1:1 randomized controlled trial. Participants will be randomly assigned to receive oral taurine (3 g/day) or an indistinguishable placebo for 6 months, stratified by (a) diabetes mellitus status and (b) age > 45 years. Assuming non-informative priors, posterior probabilities of effectiveness in reducing glycated hemoglobin (HbA1c) will be evaluated after enrollment of 20, 40, and 60 participants, if outcome data are available at those timepoints, to determine whether the trial should be stopped early for futility or superiority, prior to the planned total enrollment of 80 participants (protocol 1.4 on 19th September 2025). OUTCOMES: The primary outcome is the proportion of participants achieving any reduction in HbA1c at 6 months compared with baseline. Secondary outcomes include changes in plasma lipid levels, blood pressure, PhenoAge, body weight, and skin autofluorescence index. DISCUSSION: This phase II trial applies a Bayesian-optimized design to evaluate the potential health benefits of oral taurine supplementation. The findings will inform whether a sufficiently powered phase III randomized controlled trial is warranted to define the role of taurine in promoting metabolic health.
trial registrationThis trial is registered with the Chinese Clinical Trial registry (https://www.chictr.org.cn/hvshowprojectEN.html?id=277124&v=1.02025-05-21; Identifier: ChiCTR2500102879).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.